A promising new cancer marker: Long noncoding RNA EGFR-AS1

Danhua Zhu; Xiaoxi Ouyang; Yanhong Zhang; Xiaopeng Yu; Kunkai Su; Lanjuan Li

doi:10.3389/fonc.2023.1130472

A promising new cancer marker: Long noncoding RNA EGFR-AS1

Front Oncol. 2023 Feb 24:13:1130472. doi: 10.3389/fonc.2023.1130472. eCollection 2023.

Authors

Danhua Zhu¹, Xiaoxi Ouyang¹, Yanhong Zhang¹, Xiaopeng Yu¹, Kunkai Su¹, Lanjuan Li¹

Affiliation

¹ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Abstract

Cancer consists of a group of diseases with the salient properties of an uncontrolled cell cycle, metastasis, and evasion of the immune response, mainly driven by the genomic instability of somatic cells and the physicochemical environment. Long noncoding RNAs (lncRNAs) are defined as noncoding RNAs with a length of more than 200 nucleotides. LncRNA dysregulation participates in diverse disease types and is tightly associated with patient clinical features, such as age, disease stage, and prognosis. In addition, an increasing number of lncRNAs have been confirmed to regulate a series of biological and pathological processes through numerous mechanisms. The lncRNA epidermal growth factor receptor antisense RNA 1 (EGFR-AS1) was recently discovered to be aberrantly expressed in many types of diseases, particularly in cancers. A high level of EGFR-AS1 was demonstrated to correlate with multiple patient clinical characteristics. More importantly, EGFR-AS1 was found to be involved in the mediation of various cellular activities, including cell proliferation, invasion, migration, chemosensitivity, and stemness. Therefore, EGFR-AS1 is a promising marker for cancer management. In this review, we introduce the expression profile, molecular mechanisms, biological functions, and clinical value of EGFR-AS1 in cancers.

Keywords: lncRNA; EGFR-AS1; clinical values; expression; functions.

Publication types

Review

Grants and funding

This study was funded by the National Key Research and Development Program of China (2021YFC230180, 2019YFC0840600, and 2019YFC0840609) and the Fundamental Research Funds for the Central Universities (2022ZFJH003).